Learn More
17031 Background: Pemetrexed and gemcitabine have shown to be active agents in the treatment of locally advanced or metastatic NSCLC with favorable toxicity profiles. A recent phase I study examined(More)
PURPOSE This study aimed to identify molecular determinants of sensitivity of non-small cell lung cancer (NSCLC) to anti-insulin-like growth factor receptor (IGF-IR) therapy. EXPERIMENTAL DESIGN A(More)
INTRODUCTION The purpose of this study was to describe treatment use patterns and outcomes with single-agent erlotinib among patients with advanced non-small-cell lung cancer (NSCLC) in the community(More)
wnloaded pose: This study aimed to identify molecular determinants of sensitivity of non–small cell lung (NSCLC) to anti–insulin-like growth factor receptor (IGF-IR) therapy. erimental Design: A(More)
  • 1